Kseniia D. Ievleva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kseniia D. Ievleva has a total of 196 co-authors. Here are the top co-authors by number of shared publications:
- Tatyana A. Bairova
Scientific centre for Family Health and Human Reproduction Problems
10 shared publications - Irina N. Danusevich
Scientific centre for Family Health and Human Reproduction Problems
9 shared publications - Larisa Victorovna Suturina
Scientific centre for Family Health and Human Reproduction Problems
9 shared publications - Iana Gennad'Evna Nadeliaeva
Scientific centre for Family Health and Human Reproduction Problems
6 shared publications - Lyubov Ilijinichna Kolesnikova
Scientific centre for Family Health and Human Reproduction Problems
6 shared publications - Lyudmila M. Lazareva
Scientific centre for Family Health and Human Reproduction Problems
6 shared publications
Latest Publications
- 30 December 2025
- Published by Bionika Media in Akusherstvo i ginekologiia
- Vol. 12_2025, 88-96
Association between extradiol and progesterone levels and chronic endometritis in women with reproductive disorders
- 30 December 2025
- Published by Bionika Media in Akusherstvo i ginekologiia
- Vol. 12_2025, 88-96
Association between extradiol and progesterone levels and chronic endometritis in women with reproductive disorders
- 17 December 2025
- Published by FSPSI SCFHHRP in Acta Biomedica Scientifica
- Vol. 10 (5) , 52-59
Under what conditions is uterine myoma in women of reproductive age associated with the use of combined oral contraceptives?
Uterine myoma (UM) is a common benign tumor of smooth muscle cells of the myometrium, which is often associated with metabolic disorders. Hormonal contraceptives are used to control the duration and volume of menstrual bleeding in UM. At the same time, data on the relationship between the use of combined oral contraceptives (COCs) and uterine myoma are contradictory. The aim. To identify the relationship between uterine fibroids and the use of combined oral contraceptives in women of reproductive age, taking into account their ethnicity and the presence of metabolic disorders. Materials and methods. The results of a re-analysis of a cross-sectional study conducted earlier in Eastern Siberia (2016–2019) are presented. A total of 1347 women of reproductive age (34.33 ± 6.37 years) were included in the study, of which 198 participants had uterine fibroids. The study methods included a questionnaire survey, general clinical and gynecological examinations, pelvic ultrasound, and statistical analysis. Results. It was found that an increase in the likelihood of detecting uterine fibroids is associated with the use of COCs in the presence of metabolic syndrome and only in the Caucasian subpopulation (OR 3.287; 95% CI (1.490; 7.253)). The use of COCs is a factor associated with uterine fibroids in women with a BMI of more than 30 kg/m2, due to the subpopulation of Caucasian ethnicity, for whom the likelihood of having uterine fibroids is 6 times higher when using COCs than when not using COCs (OR 6.253, 95% CI (1.857; 21.054)). For Caucasians, the association between COC use and uterine fibroids was also demonstrated in patients with a BMI of less than 25 kg/m2 (OR 2.521; 95% CI (1.255; 5.064). Conclusion. In women of reproductive age, the association between uterine fibroids and the use of combined oral contraceptives is observed in women of Caucasian ethnicity. The presence of metabolic disorders is a key co-factor in the association between uterine fibroids and the use of hormonal contraceptives.
- 17 December 2025
- Published by FSPSI SCFHHRP in Acta Biomedica Scientifica
- Vol. 10 (5) , 52-59
Under what conditions is uterine myoma in women of reproductive age associated with the use of combined oral contraceptives?
Uterine myoma (UM) is a common benign tumor of smooth muscle cells of the myometrium, which is often associated with metabolic disorders. Hormonal contraceptives are used to control the duration and volume of menstrual bleeding in UM. At the same time, data on the relationship between the use of combined oral contraceptives (COCs) and uterine myoma are contradictory. The aim. To identify the relationship between uterine fibroids and the use of combined oral contraceptives in women of reproductive age, taking into account their ethnicity and the presence of metabolic disorders. Materials and methods. The results of a re-analysis of a cross-sectional study conducted earlier in Eastern Siberia (2016–2019) are presented. A total of 1347 women of reproductive age (34.33 ± 6.37 years) were included in the study, of which 198 participants had uterine fibroids. The study methods included a questionnaire survey, general clinical and gynecological examinations, pelvic ultrasound, and statistical analysis. Results. It was found that an increase in the likelihood of detecting uterine fibroids is associated with the use of COCs in the presence of metabolic syndrome and only in the Caucasian subpopulation (OR 3.287; 95% CI (1.490; 7.253)). The use of COCs is a factor associated with uterine fibroids in women with a BMI of more than 30 kg/m2, due to the subpopulation of Caucasian ethnicity, for whom the likelihood of having uterine fibroids is 6 times higher when using COCs than when not using COCs (OR 6.253, 95% CI (1.857; 21.054)). For Caucasians, the association between COC use and uterine fibroids was also demonstrated in patients with a BMI of less than 25 kg/m2 (OR 2.521; 95% CI (1.255; 5.064). Conclusion. In women of reproductive age, the association between uterine fibroids and the use of combined oral contraceptives is observed in women of Caucasian ethnicity. The presence of metabolic disorders is a key co-factor in the association between uterine fibroids and the use of hormonal contraceptives.
- Open Access
- 19 November 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (22) , 2929
Personalized Low-Invasive Approach to Chronic Endometritis Evaluation in Premenopausal Women: Machine Learning-Based Modeling
Background/Objectives: Chronic endometritis (CE) is a well-known risk factor for recurrent implantation failure. However, the traditional approach to CE diagnosis has several drawbacks. On the other hand, there is a lot of evidence that some clinical, instrumental, and/or laboratory parameters of patients are associated with CE. The aim of this study is to build a CE prediction model using machine learning tools based on low-invasive pathological features. Methods: The data of 108 women (44 with and 64 without CE) from a multicenter perspective cross-sectional study was included in this study. Basic characteristics, reproductive history, laboratory and ultrasound indicators, and immunohistochemistry results were collected. Binary feature selection was performed using forward stepwise selection with logistic regression as the evaluation criterion. For each feature configuration, a gradient-boosting model was trained on decision trees with a binary logistic loss function. The models were evaluated and compared on test data using standard metrics. Results: We built five comparable predictive models for CE. The models yielded the following AUCs (95% CI): Model 1 (seven indicators)—0.704 (0.5170, 0.8907), Model 2 (seven indicators)—0.673 (0.4716, 0.8745), Model 3 (nine indicators)—0.677 (0.4916, 0.8622), Model 4 (five indicators)—0.758 (0.5913, 0.9241), and Model 5 (five indicators)—0.769 (0.5913, 0.9241). Models 2 and 5 have the better recall and precision values, but the differences were not significant. SHAP values indicated that serum adiponectin level (Model 2) and SHBG (Model 5) had the greatest association with CE risks. Conclusions: Models 2 and 5 show the most promising potential for clinical application, as they demonstrate superior recall and precision metrics and require assessment of only 5–7 risk markers (with only a few being non-routine) for their implementation.
- 19 November 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (22) , 2929
Open AccessPersonalized Low-Invasive Approach to Chronic Endometritis Evaluation in Premenopausal Women: Machine Learning-Based Modeling
Background/Objectives: Chronic endometritis (CE) is a well-known risk factor for recurrent implantation failure. However, the traditional approach to CE diagnosis has several drawbacks. On the other hand, there is a lot of evidence that some clinical, instrumental, and/or laboratory parameters of patients are associated with CE. The aim of this study is to build a CE prediction model using machine learning tools based on low-invasive pathological features. Methods: The data of 108 women (44 with and 64 without CE) from a multicenter perspective cross-sectional study was included in this study. Basic characteristics, reproductive history, laboratory and ultrasound indicators, and immunohistochemistry results were collected. Binary feature selection was performed using forward stepwise selection with logistic regression as the evaluation criterion. For each feature configuration, a gradient-boosting model was trained on decision trees with a binary logistic loss function. The models were evaluated and compared on test data using standard metrics. Results: We built five comparable predictive models for CE. The models yielded the following AUCs (95% CI): Model 1 (seven indicators)—0.704 (0.5170, 0.8907), Model 2 (seven indicators)—0.673 (0.4716, 0.8745), Model 3 (nine indicators)—0.677 (0.4916, 0.8622), Model 4 (five indicators)—0.758 (0.5913, 0.9241), and Model 5 (five indicators)—0.769 (0.5913, 0.9241). Models 2 and 5 have the better recall and precision values, but the differences were not significant. SHAP values indicated that serum adiponectin level (Model 2) and SHBG (Model 5) had the greatest association with CE risks. Conclusions: Models 2 and 5 show the most promising potential for clinical application, as they demonstrate superior recall and precision metrics and require assessment of only 5–7 risk markers (with only a few being non-routine) for their implementation.
- Open Access
- 5 November 2024
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 70 (5) , 106-114
The role of leptin in endometrium disorders: literature review
Leptin is not only the main regulator of energy balance, but also it affects the reproductive and immune systems. Leptin and its receptors are expressed in the endometrium and are actively involved in the embryo implantation. According to numerous studies, expression and level changes of leptin are associated with the inflammatory and autoimmune diseases, including endometriosis and chronic endometritis. Hyperplastic and inflammatory diseases of the uterus are accompanied by a violation of the receptivity of the endometrium due to the dysregulation of many factors involved in proliferation, vascularization and decidualization of cells. Activity of most of these factors is due to the leptin action, however, there are no studies of the direct effect of leptin in the pathogenesis of disorders of the endometrium in hyperplastic and inflammatory diseases.Thus, the purpose of this literature review was to describe the putative molecular mechanisms of the effect of leptin on the development of endometrial pathology.Literature search was carried out from 03/20/2023 to 05/11/2023 using scientific literature databases: NCBI PubMed, Google Scholar (foreign sources), Cyberleninka, Elibrary (domestic sources): references for the period 1995-2023 were analyzed. The following keywords were used for the search: leptin, endometrial dysfunction, endometrial receptivity, inflammation, pelvic inflammatory disease.
- 5 November 2024
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 70 (5) , 106-114
Open AccessThe role of leptin in endometrium disorders: literature review
Leptin is not only the main regulator of energy balance, but also it affects the reproductive and immune systems. Leptin and its receptors are expressed in the endometrium and are actively involved in the embryo implantation. According to numerous studies, expression and level changes of leptin are associated with the inflammatory and autoimmune diseases, including endometriosis and chronic endometritis. Hyperplastic and inflammatory diseases of the uterus are accompanied by a violation of the receptivity of the endometrium due to the dysregulation of many factors involved in proliferation, vascularization and decidualization of cells. Activity of most of these factors is due to the leptin action, however, there are no studies of the direct effect of leptin in the pathogenesis of disorders of the endometrium in hyperplastic and inflammatory diseases.Thus, the purpose of this literature review was to describe the putative molecular mechanisms of the effect of leptin on the development of endometrial pathology.Literature search was carried out from 03/20/2023 to 05/11/2023 using scientific literature databases: NCBI PubMed, Google Scholar (foreign sources), Cyberleninka, Elibrary (domestic sources): references for the period 1995-2023 were analyzed. The following keywords were used for the search: leptin, endometrial dysfunction, endometrial receptivity, inflammation, pelvic inflammatory disease.
- Open Access
- 22 July 2024
- Published by FSPSI SCFHHRP in Acta Biomedica Scientifica
- Vol. 9 (3) , 38-48
Diagnostic significance of interleukin levels in blood serum in premenopausal women with chronic endometritis and normal weight or overweight
Background. Chronic endometritis (CE) is an inflammatory hysteropathy causing miscarriage and infertility. High invasiveness of the main method of CE diagnosis and vague clinical picture necessitate the need for the development of less invasive approaches to establish the presence of this disease.The aim of the study. To establish a significant association of the concentration of pro- and anti-inflammatory interleukins in the blood serum with the presence of chronic endometritis in premenopausal women without concomitant endocrine diseases.Materials and methods. This re-analysis of the data is based on the results of a cross-sectional study conducted between May 2017 and December 2019 which included 198 premenopausal women. In all participants, body weight and height were measured with the calculation of the body mass index, the concentration of Creactive protein, pro- and anti-inflammatory cytokines in the blood serum was determined, and a pipelle biopsy was performed to determine the CD138 expression in the endometrial stroma. Non-parametric methods, as well as ROC analysis, were used for statistical analysis.Results. 86 women were included in the re-analysis of the data, 37 of them had a confirmed diagnosis of chronic endometritis. Statistically significantly higher values of interleukin 1 (IL-1) concentration (p = 0.0028) and IL-1/tumor necrosis factor α ratio (p < 0.001) were determined in women with CE and normal body weight; threshold values of these parameters were ≥ 1.35 pg/ml (sensitivity 75 %, specificity 83 %; 95% confidence interval (95% CI): 0.88–2.15) and ≥ 1.03 (sensitivity 85 %, specificity 78 %; 95% CI: 0.81–1.27) respectively. Such a relationship was not revealed in women with overweight.Conclusions. The obtained results can be the basis for conducting a larger-scale study with determining the concentration of cytokines not only in the blood serum, but also in the endometrium of women with CE, which will allow the development of a minimally invasive method for determining the risk of the presence of chronic endometritis in premenopausal women.
- 22 July 2024
- Published by FSPSI SCFHHRP in Acta Biomedica Scientifica
- Vol. 9 (3) , 38-48
Open AccessDiagnostic significance of interleukin levels in blood serum in premenopausal women with chronic endometritis and normal weight or overweight
Background. Chronic endometritis (CE) is an inflammatory hysteropathy causing miscarriage and infertility. High invasiveness of the main method of CE diagnosis and vague clinical picture necessitate the need for the development of less invasive approaches to establish the presence of this disease.The aim of the study. To establish a significant association of the concentration of pro- and anti-inflammatory interleukins in the blood serum with the presence of chronic endometritis in premenopausal women without concomitant endocrine diseases.Materials and methods. This re-analysis of the data is based on the results of a cross-sectional study conducted between May 2017 and December 2019 which included 198 premenopausal women. In all participants, body weight and height were measured with the calculation of the body mass index, the concentration of Creactive protein, pro- and anti-inflammatory cytokines in the blood serum was determined, and a pipelle biopsy was performed to determine the CD138 expression in the endometrial stroma. Non-parametric methods, as well as ROC analysis, were used for statistical analysis.Results. 86 women were included in the re-analysis of the data, 37 of them had a confirmed diagnosis of chronic endometritis. Statistically significantly higher values of interleukin 1 (IL-1) concentration (p = 0.0028) and IL-1/tumor necrosis factor α ratio (p < 0.001) were determined in women with CE and normal body weight; threshold values of these parameters were ≥ 1.35 pg/ml (sensitivity 75 %, specificity 83 %; 95% confidence interval (95% CI): 0.88–2.15) and ≥ 1.03 (sensitivity 85 %, specificity 78 %; 95% CI: 0.81–1.27) respectively. Such a relationship was not revealed in women with overweight.Conclusions. The obtained results can be the basis for conducting a larger-scale study with determining the concentration of cytokines not only in the blood serum, but also in the endometrium of women with CE, which will allow the development of a minimally invasive method for determining the risk of the presence of chronic endometritis in premenopausal women.
- Open Access
- 29 December 2022
- Published by FSPSI SCFHHRP in Acta Biomedica Scientifica
- Vol. 7 (6) , 92-101
The experience in the development and validation of method for testosterone measurement in blood serum of premenopausal women using HPLC-MS/MS
Testosterone assessment is essential for detecting biochemical hyperandrogenism, one of the important diagnostic criteria of polycystic ovary syndrome (PCOS) both in clinical practice and in epidemiological studies. Currently, tandem liquid chromatography-mass spectrometry (LC-MS/MS) is the most preferred technique to measure testosterone level in women. Its validation is important to reproducibility of androgen tests results for clinical practice and for epidemiological studies of the prevalence PCOS.The aim of the study. To develop and validate a method for determining total testosterone in blood serum using highly efficient LC-MS/MS to assess androgenemia in the epidemiological study of the prevalence of PCOS and its phenotypes in Eastern Siberia (ESPEP STUDY).Materials and methods. We determined a total testosterone level in serum blood using triple quadrupole mass spectrometer LCMS-8060 (Shimadzu, Japan). The protocol of technique was developed using self-prepared purified human testosteronefree serum with a known concentration of analyzed compound. We used the serum samples of women of reproductive age to test the developed method.Results. Optimum chromatographic conditions were obtained with a Kromasil 100-2.5-C18 column (2.1 mm × 100 mm; AkzoNobel, Netherlands), and an isocratic elution mode using a mobile phase consisting of acetonitrile and 0.1 % aqueous solution of formic acid. The total flow rate was 0.35 ml/min. The lower limit of quantification was 5 ng/dl with an average accuracy of 100.2 %. During the approbation of the method in a test population sample of 1138 premenopausal women (mean age – 34.3 ± 6.3 years), the median testosterone concentration was 26.9 ng/dl.Conclusion. It was found that the proposed method for determining testosterone in blood serum has acceptable linearity and reproducibility and meets the requirements for bioanalytical methods under the regulatory documentation. This method can be used for clinical practice and epidemiological study of the prevalence of PCOS.
- 29 December 2022
- Published by FSPSI SCFHHRP in Acta Biomedica Scientifica
- Vol. 7 (6) , 92-101
Open AccessThe experience in the development and validation of method for testosterone measurement in blood serum of premenopausal women using HPLC-MS/MS
Testosterone assessment is essential for detecting biochemical hyperandrogenism, one of the important diagnostic criteria of polycystic ovary syndrome (PCOS) both in clinical practice and in epidemiological studies. Currently, tandem liquid chromatography-mass spectrometry (LC-MS/MS) is the most preferred technique to measure testosterone level in women. Its validation is important to reproducibility of androgen tests results for clinical practice and for epidemiological studies of the prevalence PCOS.The aim of the study. To develop and validate a method for determining total testosterone in blood serum using highly efficient LC-MS/MS to assess androgenemia in the epidemiological study of the prevalence of PCOS and its phenotypes in Eastern Siberia (ESPEP STUDY).Materials and methods. We determined a total testosterone level in serum blood using triple quadrupole mass spectrometer LCMS-8060 (Shimadzu, Japan). The protocol of technique was developed using self-prepared purified human testosteronefree serum with a known concentration of analyzed compound. We used the serum samples of women of reproductive age to test the developed method.Results. Optimum chromatographic conditions were obtained with a Kromasil 100-2.5-C18 column (2.1 mm × 100 mm; AkzoNobel, Netherlands), and an isocratic elution mode using a mobile phase consisting of acetonitrile and 0.1 % aqueous solution of formic acid. The total flow rate was 0.35 ml/min. The lower limit of quantification was 5 ng/dl with an average accuracy of 100.2 %. During the approbation of the method in a test population sample of 1138 premenopausal women (mean age – 34.3 ± 6.3 years), the median testosterone concentration was 26.9 ng/dl.Conclusion. It was found that the proposed method for determining testosterone in blood serum has acceptable linearity and reproducibility and meets the requirements for bioanalytical methods under the regulatory documentation. This method can be used for clinical practice and epidemiological study of the prevalence of PCOS.
- Open Access
- 22 December 2022
- Published by MDPI AG in Diagnostics
- Vol. 13 (1) , 33
Establishing Normative Values to Determine the Prevalence of Biochemical Hyperandrogenism in Premenopausal Women of Different Ethnicities from Eastern Siberia
Androgen assessment is a key element for diagnosing polycystic ovary syndrome (PCOS), and defining a “normal” level of circulating androgens is critical for epidemiological studies. We determined the upper normal limits (UNLs) for androgens in a population-based group of premenopausal “healthy control” women, overall and by ethnicity (Caucasian and Asian), in the cross-sectional Eastern Siberia PCOS Epidemiology and Phenotype (ESPEP) Study (ClinicalTrials.gov ID: NCT05194384) conducted in 2016–2019. Overall, we identified a “healthy control” group consisting of 143 healthy premenopausal women without menstrual dysfunction, hirsutism, polycystic ovaries, or medical disorders. We analyzed serum total testosterone (TT) by using liquid chromatography with tandem mass spectrometry (LC-MS/MS), and DHEAS, sex-hormone-binding globulin (SHBG), TSH, prolactin, and 17-hydroxyprogesterone (17OHP) were assessed with an enzyme-linked immunosorbent assay (ELISA). The UNLs for the entire population for the TT, free androgen index (FAI), and DHEAS were determined as the 98th percentiles in healthy controls as follows: 67.3 (95% confidence interval (CI): 48.1, 76.5) ng/dl, 5.4 (3.5, 14.0), and 355 (289, 371) μg/dl, respectively. The study results demonstrated that the UNLs for TT and FAI varied by ethnicity, whereas the DHEAS UNLs were comparable in the ethnicities studied.
- 22 December 2022
- Published by MDPI AG in Diagnostics
- Vol. 13 (1) , 33
Open AccessEstablishing Normative Values to Determine the Prevalence of Biochemical Hyperandrogenism in Premenopausal Women of Different Ethnicities from Eastern Siberia
Androgen assessment is a key element for diagnosing polycystic ovary syndrome (PCOS), and defining a “normal” level of circulating androgens is critical for epidemiological studies. We determined the upper normal limits (UNLs) for androgens in a population-based group of premenopausal “healthy control” women, overall and by ethnicity (Caucasian and Asian), in the cross-sectional Eastern Siberia PCOS Epidemiology and Phenotype (ESPEP) Study (ClinicalTrials.gov ID: NCT05194384) conducted in 2016–2019. Overall, we identified a “healthy control” group consisting of 143 healthy premenopausal women without menstrual dysfunction, hirsutism, polycystic ovaries, or medical disorders. We analyzed serum total testosterone (TT) by using liquid chromatography with tandem mass spectrometry (LC-MS/MS), and DHEAS, sex-hormone-binding globulin (SHBG), TSH, prolactin, and 17-hydroxyprogesterone (17OHP) were assessed with an enzyme-linked immunosorbent assay (ELISA). The UNLs for the entire population for the TT, free androgen index (FAI), and DHEAS were determined as the 98th percentiles in healthy controls as follows: 67.3 (95% confidence interval (CI): 48.1, 76.5) ng/dl, 5.4 (3.5, 14.0), and 355 (289, 371) μg/dl, respectively. The study results demonstrated that the UNLs for TT and FAI varied by ethnicity, whereas the DHEAS UNLs were comparable in the ethnicities studied.
- Open Access
- 20 September 2022
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 11
FSH-blocking therapeutic for osteoporosis
Pharmacological and genetic studies over the past decade have established the follicle-stimulating hormone (FSH) as an actionable target for diseases affecting millions, namely osteoporosis, obesity, and Alzheimer’s disease. Blocking FSH action prevents bone loss, fat gain, and neurodegeneration in mice. We recently developed a first-in-class, humanized, epitope-specific FSH-blocking antibody, MS-Hu6, with a KD of 7.52 nM. Using a Good Laboratory Practice (GLP)-compliant platform, we now report the efficacy of MS-Hu6 in preventing and treating osteoporosis in mice and parameters of acute safety in monkeys. Biodistribution studies using 89Zr-labeled, biotinylated or unconjugated MS-Hu6 in mice and monkeys showed localization to bone and bone marrow. The MS-Hu6 displayed a β phase t½ of 7.5 days (180 hr) in humanized Tg32 mice. We tested 217 variations of excipients using the protein thermal shift assay to generate a final formulation that rendered MS-Hu6 stable in solution upon freeze-thaw and at different temperatures, with minimal aggregation, and without self-, cross-, or hydrophobic interactions or appreciable binding to relevant human antigens. The MS-Hu6 showed the same level of “humanness” as human IgG1 in silico and was non-immunogenic in ELISpot assays for IL-2 and IFN-γ in human peripheral blood mononuclear cell cultures. We conclude that MS-Hu6 is efficacious, durable, and manufacturable, and is therefore poised for future human testing.
- 20 September 2022
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 11
Open AccessFSH-blocking therapeutic for osteoporosis
Pharmacological and genetic studies over the past decade have established the follicle-stimulating hormone (FSH) as an actionable target for diseases affecting millions, namely osteoporosis, obesity, and Alzheimer’s disease. Blocking FSH action prevents bone loss, fat gain, and neurodegeneration in mice. We recently developed a first-in-class, humanized, epitope-specific FSH-blocking antibody, MS-Hu6, with a KD of 7.52 nM. Using a Good Laboratory Practice (GLP)-compliant platform, we now report the efficacy of MS-Hu6 in preventing and treating osteoporosis in mice and parameters of acute safety in monkeys. Biodistribution studies using 89Zr-labeled, biotinylated or unconjugated MS-Hu6 in mice and monkeys showed localization to bone and bone marrow. The MS-Hu6 displayed a β phase t½ of 7.5 days (180 hr) in humanized Tg32 mice. We tested 217 variations of excipients using the protein thermal shift assay to generate a final formulation that rendered MS-Hu6 stable in solution upon freeze-thaw and at different temperatures, with minimal aggregation, and without self-, cross-, or hydrophobic interactions or appreciable binding to relevant human antigens. The MS-Hu6 showed the same level of “humanness” as human IgG1 in silico and was non-immunogenic in ELISpot assays for IL-2 and IFN-γ in human peripheral blood mononuclear cell cultures. We conclude that MS-Hu6 is efficacious, durable, and manufacturable, and is therefore poised for future human testing.
- Open Access
- 4 July 2022
- Published by MDPI AG in Metabolites
- Vol. 12 (7) , 620
The Leydig Steroid Cell Tumor in a Postmenopausal Woman with Clinical and Biochemical Hyperandrogenism: A Case Report
Leydig cell tumors (LCTs) refer to tumors of the stroma of the genital strand, which are found mainly in postmenopausal women. The diagnosis of LCTs in postmenopausal women is associated with specific difficulties and is based on the identification of hyperandrogenism with clinical manifestations of virilization, which has an erased picture in postmenopausal women. LCTs require differential diagnosis with other causes of hyperandrogenism. We present the clinical case of a 55-year-old Russian postmenopausal patient with LCTs of the right ovary, significantly increased levels of androgens, and rapidly progressive clinical signs of hyperandrogenism. The patient underwent laparoscopic bilateral salpingo-oophorectomy, and the androgen indices reached average values by the first and third month after surgery. This case demonstrates that LCTs are often benign with a good prognosis and normalization of the clinical and laboratory manifestations of hyperandrogenism after surgical treatment. The type of surgery performed (bilateral salpingo-oophorectomy rather than unilateral) is recommended as the treatment of choice for LCTs in postmenopausal patients.
- 4 July 2022
- Published by MDPI AG in Metabolites
- Vol. 12 (7) , 620
Open AccessThe Leydig Steroid Cell Tumor in a Postmenopausal Woman with Clinical and Biochemical Hyperandrogenism: A Case Report
Leydig cell tumors (LCTs) refer to tumors of the stroma of the genital strand, which are found mainly in postmenopausal women. The diagnosis of LCTs in postmenopausal women is associated with specific difficulties and is based on the identification of hyperandrogenism with clinical manifestations of virilization, which has an erased picture in postmenopausal women. LCTs require differential diagnosis with other causes of hyperandrogenism. We present the clinical case of a 55-year-old Russian postmenopausal patient with LCTs of the right ovary, significantly increased levels of androgens, and rapidly progressive clinical signs of hyperandrogenism. The patient underwent laparoscopic bilateral salpingo-oophorectomy, and the androgen indices reached average values by the first and third month after surgery. This case demonstrates that LCTs are often benign with a good prognosis and normalization of the clinical and laboratory manifestations of hyperandrogenism after surgical treatment. The type of surgery performed (bilateral salpingo-oophorectomy rather than unilateral) is recommended as the treatment of choice for LCTs in postmenopausal patients.